Concomitant medications and comorbidities
malignancies, prostate and breast cancers, PPV-MF, PET-MF
MALIGNANCIES
Patients had a median number of three comorbidities when entering the trial (Table Comorbidities at time of and/or before entering the trial, coded according to MedDRA version 23.1 (Importantly, pre-existing malignancies were found in 72 patients (15.5%); these were similarly distributed among PMF, PPV-MF, and PET-MF patients, with the most frequent malignancies being prostate and breast cancers.The most frequent pre-existing cytoreductive medication was hydroxyurea (30.2%), followed by anagrelide (approximately 5%), while only six patients had received interferon. Deferasirox had been administered in 3.9% of patients.